{
  "docId": "019de077-62f6-7619-b3d4-93c2a4cadb7d",
  "docSlug": "491e9b124c7ffd2bd1d8681cd2680c6c",
  "documentTitle": "OmniAb | Results Presentation Deck | 16 slides",
  "authorId": "omniab",
  "authorName": "OmniAb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 16,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 7,
  "notes": "The chart shows a steady upward trend in clinical programs over time.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-62f6-7619-b3d4-93c2a4cadb7d/7",
  "deckHref": "/decks/019de077-62f6-7619-b3d4-93c2a4cadb7d",
  "deckJsonHref": "/decks/019de077-62f6-7619-b3d4-93c2a4cadb7d.json",
  "deckAnchorHref": "/decks/019de077-62f6-7619-b3d4-93c2a4cadb7d#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.25,
        "x": 0.05,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Number of Active Clinical Programs and Approved Products",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5928980f-883e-4c47-9656-7b31e600a190",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "(1) See our SEC filings for Active Clinical Programs and Approved Products definition\n(2) Value as of 9/30/2024 does not include ALTA-002... and value is net of clinical-stage attrition...\n(3) Reference https://clinicaltrials.gov/study/NCT06573294 and https://clinicaltrials.gov/study/NCT06577337",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d582defc-bf8f-41e0-9cb8-24045ab9885e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.65,
        "x": 0.27,
        "y": 0.25
      },
      "kind": "list",
      "text": "33 active clinical programs and approved products as of 9/30/2024(2)\nGenmab’s GEN1057 (bispecific anti-FAPα x DR4) and Merck KGaA’s M5542 (CTLA-4 ECD fused to anti-OX40L) each entered Phase 1 clinical trials(3) in Q3\nThree new OmniAb-derived programs have entered human clinical trials through 9/30/2024, and we see potential for one to three more entries into clinical development for novel OmniAb-derived antibodies in Q4 2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8d9b6a7-bd22-4aad-aedd-f6c3529c838f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Active Clinical Programs and Approved Products",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff8a7cbf-ab14-4e58-bbd5-ab085bf34e10",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 9,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "ef4536a9-bf42-4eb8-a5ae-6239cca5f481",
      "evidence": "Emphasis on Q3 momentum in all key metrics",
      "position": 0,
      "objective": "Highlighting the value of OmniAb's growth",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}